We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- KRAS pathway and mutations in cancer (1)
- KRAS: an isoform of Ras family of small GTPase
- KRAS pathway and mutations in cancer (2)
- Ras: A molecular switch
- Ras: A signalling hub for EGF signalling
- KRAS pathway and mutations in cancer (3)
- RAS oncogenic mutation hotspot
- G12 is proximal to the γ-phosphate of GTP
- Oncogenic KRAS
- KRAS pathway and mutations in cancer (4)
- KRAS transduces the growth factor signal to multiple effectors
- Ras: A hub switch for cell signalling
- Oncogenic Ras overexpression hyperactivates downstream pathways
- Examining the effect of KRAS chromosomal oncogenic mutations
- Endogenously expressed oncogenic Ras phenotypes
- Endogenously expressed oncogenic Ras
- KRAS cell lines generated using hTERT RPE-1
- Generation of KRAS.G12X cell lines
- KRAS.G12V/D/C cells show an increase in cell proliferation and motility
- KRAS.G12V/D/C cells attenuated the ERK activation as WT cells
- KRAS.G12V/D/C cells attenuated the AKT activation as WT cells
- KRAS.G12V/D cells are more sensitive to MEK inhibitors than WT cells
- Oncogenic Ras targets specific pathways
- KRAS pathway and mutations in cancer (5)
- Raf-MEK-ERK signalling axis and oncogenic Ras signalling
- KRAS dependent gene expression analysis
- Raf-MEK-ERK signalling axis in oncogenic Ras signalling
- KRAS pathway and mutations in cancer (6)
- Ras-Rgl2-RalA/B signalling axis plays a significant role in oncogenic Ras signalling
- The importance of the Ras-Rgl2-RalA/B signalling axis
- Rgl2-RalA/B signalling axis in oncogenic Ras signalling
- Biolayer Interferometry (BLI)
- G12V oncogenic mutation
- A 2:2 tetramer of KRas4BG12V:Rgl2RA complex in the crystal structure
- Striking similarity
- Ras:RalGEF interaction mode may be distinct from others
- Conclusions
- Acknowledgements
- Financial disclosures
Topics Covered
- Ras family of small GTPases
- Ras acts as a molecular switch
- Oncogenic mutations in KRAS
- Effect of endogenous and overexpressed KRAS
- Raf-MEK-ERK signalling axis
- KRAS-Rgl2-RalA/B signalling axis is mediates oncogenic Ras signalling
Links
Categories:
Therapeutic Areas:
External Links
Talk Citation
Tanaka, K. (2025, November 30). KRAS pathway and mutations in cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 4, 2025, from https://doi.org/10.69645/OTWL5989.Export Citation (RIS)
Publication History
- Published on November 30, 2025
Financial Disclosures
- There are no commercial/financial matters to disclose.
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is Kayoko Tanaka.
I'm a lecturer at the
University of Leicester.
I'd like to introduce
the research topic of
the KRAS Pathway and
Mutations in Cancer.
0:15
My presentation consists of
six parts as listed here.
In the first three
parts, I will summarize
the structural and biochemical
properties of KRAS
and their relevance to
oncogenic mutations.
Next, I would like to introduce
the importance of
distinguishing between
the effects of overexpression
and endogenous expression
of oncogenic KRAS mutants
as these lead to
different phenotypes.
Following that, I will discuss
the downstream pathways of KRAS.
I will highlight
the significance of
the Raf-MEK-ERK signaling axis
in KRAS oncogenic signaling.
Finally, I would like to discuss
the molecular insights into
the KRAS-Rgl2-RalA/B
signaling axis.
1:11
First, KRAS is an isoform
of the Ras family
of small GTPases.
1:19
Humans have three Ras genes,
KRAS, HRAS, and NRAS.
As the KRAS encodes
two splice variants,
KRAS4A and KRAS4B,
there are four Ras
isoforms as listed here.
The diagram represents an
NMR data-driven model of
KRAS4B PDB entry 2MSD
and is colored in the same way
as the sequence alignment.
These four isoforms are
highly conserved at
the N-terminal hub
which consists of
β1, α1, β2, β3, α2, and β4
and the linking
unstructured parts P-loop,
Switch I, Switch II.
They further contribute
to generating
a guanine nucleotide
binding pocket.
Meanwhile, the C-terminal
end is less conserved
and hence is as termed
the hypervariable region,
which contains cysteine
residues that receive
lipid modifications
that help the proteins
to anchor at the
plasma membrane.
This is the same NMR
data-driven model
of KRAS4B that I just presented,
but this time it includes
the membrane nanodisc as
the original modeled KRAS
structure was analyzed.
Mazhab-Jafari and his
colleagues performed
a paramagnetic relaxation
enhancement analysis,
type of NMR analysis,
to examine the molecular
orientation of KRAS
in relation to the
membrane nanodisc.
The C-terminal hypervariable
region is highlighted in purple
and the guanine nucleotide
is indicated in the model.
Additionally, the
modeled structure shows
the position of the magnesium
ion, which is essential
for the proper folding
of the KRAS protein.
This study emphasizes
the importance
of considering the
effects of the membrane
when investigating KRAS function
as the presence of the membrane
can impose constraints
on KRAS orientation
and the accessibility of
its interacting partners.